TY - JOUR
T1 - CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals
AU - del Campo, Marta
AU - Quesada, Carlos
AU - Vermunt, Lisa
AU - Peeters, Carel F.W.
AU - Hok-A-Hin, Yanaika S.
AU - Trieu, Calvin
AU - den Braber, Anouk
AU - Verberk, Inge M.W.
AU - Visser, Pieter J.
AU - Tijms, Betty M.
AU - van der Flier, Wiesje M.
AU - Teunissen, Charlotte E.
PY - 2024/11/11
Y1 - 2024/11/11
N2 - This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune function, neurotrophic processes, energy metabolism and endolysosomal functioning (e.g., ITGB2, CLEC5A, IGFBP-1, CST3) changed before amyloid positivity is established.
AB - This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune function, neurotrophic processes, energy metabolism and endolysosomal functioning (e.g., ITGB2, CLEC5A, IGFBP-1, CST3) changed before amyloid positivity is established.
U2 - 10.1186/s13024-024-00767-z
DO - 10.1186/s13024-024-00767-z
M3 - Comment/Letter to the editor
C2 - 39523360
AN - SCOPUS:85209475929
SN - 1750-1326
VL - 19
JO - Molecular Neurodegeneration
JF - Molecular Neurodegeneration
M1 - 82
ER -